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ABSTRACT
Objective: The present research work concerns the development of the extended release of Ritonavir floating matrix tablets, designed to prolong the 
gastric residence time, increase the drug bioavailability, and diminish the side effects of irritating drugs.
Methods: The floating tablets of Ritonavir were prepared by direct compression method using different grades of hydroxypropyl methylcellulose 
(HPMC), crospovidone, Polyox WSR 303, and sodium bicarbonate, as gas generating agent. Evaluation parameters and in vivo radiographic studies 
were conducted in suitable model.
Results: Among all formulations, F21 was chosen as optimized formulation based on evaluation parameters such as floating lag time (33 s), total 
floating time (>24 h), and in vitro dissolution studies. From in vitro dissolution studies, the optimized formulation F21 and marketed product were 
shown 98.67% and 91.46±5.02% of drug release, respectively. The main appliance of medication discharge follows zero-order kinetics and non-
Fickian transport by coupled diffusion and erosion. In vivo experiments maintained the potentials in extending the gastric residence time in the fasted 
state in beagle dogs. The mean gastric residence time of the optimized formulation found to be 330 min±40 in the stomach, where longer gastric 
residence time is an important condition for prolonged or controlled drug release and also for enhanced bioavailability.
Conclusion: From in vitro and in vivo radiographic studies, Ritonavir floating tablets estimated to provide novel choice for harmless, inexpensive, and 
extended release for the effective management of AIDS.
Keywords: Ritonavir AIDS, Floating tablets, Hydroxypropyl methylcellulose, Radiographic studies.
INTRODUCTION
Oral route is foremost common route of administering the drug due to 
the ease of formulation, low-cost, convenient for the patient, and simple 
regulatory approval process. Based on the requirement, formulations 
can be changed from immediate release to extended release using 
several polymers [1]. Gastroretentive drug delivery systems can 
valuable in the transport of medications that remain mainly engrossed 
in the duodenum and upper jejunum/those that need an absorption 
window in the gastrointestinal tract [2]. Gastroretentive floating dosage 
forms remain constantly researched and advanced stomach is a main 
absorption zone [3]. In accumulation, relatively brief gastric emptying 
time in humans, through the stomach/upper part of the intestine 
(major absorption zone), can result in incomplete medication release 
from drug delivery system, leading to reduced generally ability drug. 
Some drugs like Ritonavir demonstrates region-specific absorption in 
different regions of the intestine because of different pH conditions, 
various enzymes and endogenous constituents like bile [4].
There exist numerous methodologies toward target an exact site 
sustained/controlled release fashion [5]. Some common methodologies 
used toward increased gastric residence time of pharmaceutical dosage 
forms include floating systems, swelling and expanding systems, 
bioadhesive systems, unfolding and modified shape systems, and high-
density systems. Floating drug delivery systems have bulk density (BD) 
lower than gastric fluids and so remain buoyant in the stomach without 
distressing gastric emptying rate for a prolonged period of time [6]. While 
system remains afloat, drug released the desired rate from system [7]. 
Following drug release, residual system gets emptied from the stomach. 
However, besides a minimal gastric content needed to allow proper 
achievement buoyancy retention principle, minimal equal of floating force 
is also required keep dosage form reliably buoyant on surface meal [8].
MATERIALS AND METHODS
Materials
Ritonavir was procured from MSN Labs Ltd., Hyderabad. Hydroxypropyl 
methylcellulose (HPMC) K4M, HPMC K15M, HPMC K100M, and Polyox 
WSR 303 existed were obtained from Granules India Ltd., Hyderabad. 
Sodium bicarbonate, citric acid, PVP K 30, talc, and magnesium stearate 
existed were procured from S D Fine-Chem Ltd., Mumbai, and all other 
chemicals used existed were of analytical grade.
Methods
Micromeritic properties of final blend
Final blend of all preparations was evaluated for BD, tapped density 
(TD), compressibility index (CI), Hausner ratio, and angle of repose [9].
Formulation method
Accurately weighed amounts of polymers were in a mortar and mixed 
geometrically, and the required quantity of Ritonavir was added to the 
polymers. Sodium bicarbonate was taken separately, and the powder 
passed through sieve no 40. The whole mixture was collected in a 
plastic bag and mixed for 3 min. Magnesium stearate added and mixed 
for 5 min, and later, Talc was added and mixed for 2 min [10-12]. The 
mixture equivalent to 300 mg was compressed into tablets with 10 mm 
round concave punches, and the composition is shown in Tables 1-3.
© 2019 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons. 
org/licenses/by/4. 0/) DOI: http://dx.doi.org/10.22159/ajpcr.2019.v12i2.29196
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Evaluation of floating matrix tablets of Ritonavir
Parameters such as weight variation, thickness, hardness, and ability 
were evaluated according to the reported method [13].
In vitro buoyancy studies
The in vitro buoyancy was determined by floating lag time. The tablets 
existed placed in a 100 ml beaker containing 0.1 N hydrochloric acid 
(N HCl). Time required for tablet to rise to surface and float was 
determined as floating lag time [14].
Drug content
Twenty tablets were taken and powdered. Powder equivalent to one 
dose each transferred to a 100 ml volumetric flask and 0.1 N HCl was 
added; volume was then made up to mark with 0.1 N HCl. Solution was 
filtered and diluted suitably and drug content in samples was estimated 
using ultraviolet (UV)-spectrophotometer at 238 nm [15].
In vitro drug release studies
In vitro drug release study was performed for prepared tablets using 
USP Type II dissolution apparatus using 900 ml of 0.1 N HCl at a 
temperature of 37±0.5°C at 50 rpm. 5 ml of sample was collected at 0, 
2, 4, 6, 8, 12, 16, 20, and 24 h and the same volume of fresh media was 
replenished. Drug content in samples was estimated using UV visible 
spectrophotometer at 238 nm [16].
Release order kinetics Ritonavir tablets
In vitro release data from several formulations containing Ritonavir 
were determined kinetically using different mathematical models such 
as zero-order, first-order, Higuchi, and Korsmeyer–Peppas model [17].
Drug-excipient compatibility studies
Fourier-transform infrared spectroscopy (FTIR)
The spectral analysis can be used to identify the functional groups in 
the pure drug and drug-excipient compatibility. Pure Ritonavir FTIR 
spectra, physical mixtures, and optimized formulation were recorded 
using FTIR (SHIMADZU) [18].
Differential scanning calorimetry (DSC)
DSC studies carried out using DSC 60, having TA60 Software, Shimadzu, 
Japan. DSC thermograms were recorded for pure drug and optimized 
formulations. Accurately weighed samples were placed on aluminum 
plate, sealed with aluminum lids, and heated at a constant rate of 
5°C/min, over a temperature range of 0–250°C.
Scanning electron microscopy (SEM) studies
The surface and shape characteristics of pellets were determined by 
SEM (HITACHI, S-3700N). Photographs were taken and recorded at 
suitable magnification.
Stability studies
Stability testing was conducted at 40°C±2°C/75% RH±5% RH 3 months 
using stability chamber (ThermoLab, Mumbai). Samples were 
withdrawn at predetermined intervals of 0, 30, 60, and 90 days’ period 
according to the ICH guidelines [19]. Various in vitro parameters such 
as percentage yield, entrapment efficiency, and in vitro release studies 
were evaluated.
Tablet preparation for in vivo radiographic studies
Ritonavir tablets of 300 mg in weight existed were prepared for in 
vivo radiographic studies in beagle dogs. To make tablets X-ray opaque 
incorporation of BaSO4 necessary. For in vivo radiographic studies, 
40 mg of Ritonavir and 5 mg of PVP K 30 were replaced with BaSO4 
to ensure visibility by X-ray. Amount of X-ray opaque material in these 
tablets sufficient to ensure visibility by X-ray. Analyses confirmed that 
these tablets like tablets for in vitro testing, i.e. mechanical strength, 
floating properties, controlled drug release [20].
Ritonavir in vivo radiographic studies
Three healthy beagle dogs, weighing approximately 16 kg, existed were 
used throughout the study. In each experiment, an unanesthetized 
animal was fasted for 24 h and first radiograph was made to ensure 
the absence of radiopaque material in the stomach. Dogs swallowed 
one of the tablets and immediately afterward drank 100 ml of 
water. During experiment, dogs were not allowed to eat, but water 
existed available ad libitum. The study protocol was approved by the 
institutional animal ethics committee with No. CPCSEA/1657/IAEC/
CMRCP/PhD-15/37. For radiographic imaging, animal was positioned 
in a right lateral or ventrodorsally recumbency, and after determined 
time intervals, the radiographs of the abdomen were taken using an 
X-ray machine (General Electric Corporation, USA). Distance between 
the source of X-rays and the object was maintained similar for all 
images [21]. This allowed us to see tablet in the body of the stomach. 
At different time intervals of 0.5, 3, 4, and 6 h post-administration of 
tablets, dogs were exposed to abdominal X-ray imaging [22].
Table 1: Composition of floating matrix tablets of Ritonavir with 
HPMC K4M
Ingredients (weight in mg) Formulations
F1 F2 F3 F4 F5 F6 F7
Ritonavir 100 100 100 100 100 100 100
HPMC K4M 50 55 60 65 70 75 80
Crospovidone 50 50 50 50 40 25 20
Polyox WSR 303 20 25 30 35 40 45 50
Sodium bicarbonate 20 22 24 26 28 30 32
Citric acid 10 10 10 10 10 10 10
PVP K-30 46 34 22 10 8 11 4
Talc 2 2 2 2 2 2 2
Magnesium stearate 2 2 2 2 2 2 2
Total weight 300 300 300 300 300 300 300
HPMC: Hydroxypropyl methylcellulose
Table 2: Composition of floating matrix tablets of Ritonavir with 
HPMC K15M
Ingredients (weight in mg) Formulations
F8 F9 F10 F11 F12 F13 F14
Ritonavir 100 100 100 100 100 100 100
HPMC K15M 50 55 60 65 70 75 80
Crospovidone 50 50 50 50 40 25 20
Polyox WSR 303 20 25 30 35 40 45 50
Sodium bicarbonate 20 22 24 26 28 30 32
Citric acid 10 10 10 10 10 10 10
PVP K-30 46 34 22 10 8 11 4
Talc 2 2 2 2 2 2 2
Magnesium stearate 2 2 2 2 2 2 2
Total weight 300 300 300 300 300 300 300
HPMC: Hydroxypropyl methylcellulose
Table 3: Composition of floating matrix tablets of Ritonavir with 
HPMC K100M
Ingredients (weight in mg) Formulations
F15 F16 F17 F18 F19 F20 F21
Ritonavir 100 100 100 100 100 100 100
HPMC K100M 50 55 60 65 70 75 80
Crospovidone 50 50 50 50 40 25 20
Polyox WSR 303 20 25 30 35 40 45 50
Sodium bicarbonate 20 22 24 26 28 30 32
Citric acid 10 10 10 10 10 10 10
PVP K-30 46 34 22 10 8 11 4
Talc 2 2 2 2 2 2 2
Magnesium stearate 2 2 2 2 2 2 2
Total weight 300 300 300 300 300 300 300
HPMC: Hydroxypropyl methylcellulose
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RESULTS AND DISCUSSION
Micromeritic properties of prepared powder blend Ritonavir
The results of BD formulations bearing F1 to F21 were reported 
in the range of 0.48±0.08 g/cc–0.54±0.12 g/cc. The findings 
of TD formulations F1 to F21 were reported in the range of 
0.56±0.15 g/cc–0.62±0.22 g/cc. The angle of repose of all the 
formulations was found to be satisfactory. The formulation F21 
was having an angle of repose value of 20.01±0.01, and CI values 
existed found to be in range of 10.01–15.38%. These findings 
indicated that all batches of formulations exhibited good flow 
properties. Hausner’s ratio values were in the range of 1.10–1.26% 
and values are shown in Table 4.
Physicochemical properties of Ritonavir floating tablets
The Ritonavir floating tablets were prepared, and the compositions of 
different formulations existed are shown in Tables 1-3 and the tablets 
are shown in Fig 1.
Table 4: Micromeretic properties of prepared powder blends of Ritonavir
Formulation BD (g/cc) TD (g/cc) Angle of repose (ϴ) Carr’s index (%) Hausner ratio
F1 0.53±0.11 0.57±0.18 24˚.63±0.03 11.90 1.11
F2 0.52±0.11 0.59±0.21 26˚.21±0.05 12.67 1.14
F3 0.53±0.11 0.60±0.21 25˚.30±0.03 11.64 1.20
F4 0.51±0.10 0.62±0.22 26˚.80±0.05 12.90 1.13
F5 0.54±0.12 0.61±0.21 24˚.47±0.03 14.64 1.14
F6 0.52±0.11 0.62±0.22 25˚.98±0.03 13.90 1.16
F7 0.51±0.10 0.61±0.21 27˚.67±0.05 15.38 1.17
F8 0.51±0.10 0.60±0.21 25˚.60±0.03 14.56 1.19
F9 0.50±0.09 0.60±0.21 26˚.31±0.05 15.33 1.25
F10 0.50±0.09 0.59±0.20 24˚.98±0.03 12.38 1.24
F11 0.49±0.08 0.58±0.18 23˚.46±0.03 14.56 1.26
F12 0.53±0.11 0.62±0.22 26˚.38±0.05 14.23 1.25
F13 0.52±0.11 0.61±0.21 24˚.60±0.03 13.67 1.26
F14 0.51±0.10 0.60±0.21 25˚.67±0.03 12.45 1.24
F15 0.51±0.10 0.60±0.21 21˚.56±0.02 11.98 1.23
F16 0.52±0.11 0.59±0.20 24˚.30±0.03 12.03 1.20
F17 0.53±0.11 0.58±0.18 23˚.67±0.03 12.65 1.17
F18 0.51±0.10 0.59±0.20 22˚.74±0.02 11.08 1.18
F19 0.52±0.10 0.57±0.18 22˚.48±0.02 11.01 1.14
F20 0.49±0.08 0.58±0.18 22˚.03±0.02 11.21 1.11
F21 0.48±0.08 0.56±0.15 20˚.01±0.01 10.01 1.10
Above parameters are communicated as average±standard deviation; (n=3), BD: Bulk density, TD: Tapped density











F1 297±0.8 3.21±0.18 4.6±0.46 0.22 96.31±0.45 48 >24
F2 298±0.8 3.54±0.27 4.8±0.48 0.23 95.21±0.35 45 >24
F3 299±0.9 3.46±0.22 5.6±0.53 0.28 94.20±0.35 42 >24
F4 298±0.8 3.81±0.30 5.1±0.50 0.26 96.13±0.45 40 >24
F5  299±0.9 3.90±0.38 4.9±0.48 0.24 95.12±0.35 38 >24
F6 300±0.10 3.85±0.36 4.7±0.46 0.23 94.23±0.35 35 >24
F7 298±0.7 3.84±0.36 4.6±0.46 0.24 92.15±0.19 32 >24
F8 299±0.9 3.98±0.45 4.8±0.48 0.22 94.65±0.35 46 >24
F9 301±0.5 3.67±0.32 4.7±0.46 0.19 96.31±0.45 44 >24
F10 300±0.5 3.35±0.18 4.9±0.48 0.18 90.24±0.15 41 >24
F11 297±0.8 3.29±0.15 4.8±0.48 0.21 97.23±0.60 39 >24
F12 299±0.8 3.38±0.18 4.6±0.46 0.23 95.61±0.35 37 >24
F13 300±0.10 3.40±0.21 4.8±0.48 0.25 94.28±0.35 36 >24
F14 298±0.8 3.28±0.15 4.9±0.48 0.26 93.46±0.19 35 >24
F15 297±0.8 3.35±0.18 5.5±0.43 0.28 92.15±0.19 47 >24
F16 299±0.9 3.23±0.15 5.3±0.42 0.24 97.32±0.60 46 >24
F17 300±0.10 3.18±0.09 5.0±0.49 0.25 91.26±0.18 43 >24
F18 298±0.8 3.20±0.18 4.9±0.48 0.20 90.74±0.20 40 >24
F19 300±0.8 3.42±0.20 4.7±0.46 0.19 94.67±0.35 38 >24
F20 299±0.9 3.23±0.15 4.9±0.48 0.18 96.12±0.45 36 >24
F21 302±0.10 3.11±0.08 4.5±0.45 0.15 98.36±0.68 33 >24
*Values are expressed in mean±SD: (n=20) #Values are expressed in mean±SD: (n=3)
Figure 1: Ritonavir floating tablets
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The micromeritic parameters and evaluation parameters such as weight 
variation, thickness, hardness, friability, and drug content existed were 
found to be within limits and summarized in Tables 4 and 5, respectively.
In vitro buoyancy study
All the prepared Ritonavir dosage forms showed floating lag time of <1 
min and floated in 0.1N HCl intended for additional than 12 h (Fig. 2). 
Sodium bicarbonate content controls the floating behavior including 
the lag time. Increased sodium bicarbonate content caused rapid 
formation and entrapment of CO2 resulted in reduction floating lag 
time. Optimized formulation F21 showed minimum floating lag time of 
33 s and total floating time for formulations >24 h (Fig 3).
In vitro dissolution studies
From the results, it can be observed that the polymer HPMC K 100M 
has a controlling effect on release drug from floating matrix tablet of 
Ritonavir compared to HPMC K15 M and HPMC K 4M. The concentration 
of polymer was added in increasing order to check its drug release 
retarding ability, and F21 was considered as best one among the all the 
formulations, drug release was found to be higher 98.67±5.40, when 
compared with marketed product of 91.46±5.02 within 24 h (Figs. 4-6).
Mathematical modeling of optimized formula (F21) of Ritonavir 
floating tablets
From the results, it is apparent that the regression coefficient value 
closer to unity in case of zero-order plot, i.e., 0.990 indicates that drug 
release follows zero-order mechanism. The drug release mechanism 
of optimized Ritonavir tablets F21 was best fitting to zero-order and 
Higuchi model because of the regression coefficient, thus, mechanism 
of drug release by diffusion. Further, the n value obtained from the 
Korsmeyer–Peppas plots, i.e., 0.62 indicates non-Fickian (anomalous) 
transport. Thus, active ingredient is being released by coupled diffusion 
and erosion. The reference standard (marketed product) regression 
coefficient value is closer to unity in case of zero-order plot, i.e., 0.958, 
specifying that drug release follows zero-order mechanism. These 
data indicate lesser amount linearity once plotted by the first-order 
equation. Hence, it can be concluded that, in case of marketed product 
also, the major mechanism of drug release follows zero-order kinetics. 
However, the linearity of the optimized formulation is more when 
compared to a marketed product. Results are summarized in Table 6 
and graphs are depicted in Fig. 7-14.
Table 6: Release order kinetics of F21 and marketed product
Formulation code Zero order First order Higuchi Korsmeyer–Peppas n
F1 0.9798 0.8081 0.933 0.892 0.76
F2 0.968 0.7063 0.932 0.911 0.709
F3 0.9704 0.7353 0.916 0.927 0.77
F4 0.9783 0.7142 0.9597 0.921 0.795
F5 0.9329 0.6417 0.957 0.856 0.773
F6 0.9354 0.7068 0.9557 0.8617 0.702
F7 0.9399 0.6355 0.9603 0.8993 0.658
F8 0.973 0.7628 0.96 0.9242 0.782
F9 0.968 0.709 0.9558 0.9174 0.764
F10 0.972 0.805 0.960 0.9073 0.773
F11 0.9614 0.785 0.901 0.892 0.777
F12 0.9457 0.752 0.947 0.896 0.71
F13 0.9348 0.812 0.924 0.874 0.657
F14 0.9225 0.855 0.937 0.896 0.701
F15 0.970 0.845 0.916 0.875 0.711
F16 0.9633 0.855 0.938 0.887 0.721
F17 0.9487 0.871 0.943 0.894 0.651
F18 0.9363 0.895 0.951 0.913 0.611
F19 0.9358 0.894 0.936 0.908 0.632
F20 0.9562 0.903 0.942 0.901 0.732
F21 0.990 0.917 0.961 0.923 0.62
Marketed 0.958 0.893 0.946 0.929 0.59
Table 7: Parameters after accelerated stability study of optimized formulation F21
Parameters Temperature maintained at 40±2°C RH maintained at 75%±5%RH
Initial After 1 month After 3 months After 6 months
Drug content (%) 98.36±0.68 97.24±0.65 97.02±0.65 96.34±0.62
In vitro drug release (%) 98.67±5.40 98.21±5.39 98.02±5.25 97.36±5.15
Floating lag time 33 34 35 35
RH: Relative humidity
Figure 3: Ritonavir floating tablets after 24 h
Figure 2: Pictorial representation of floating lag time of Ritonavir 
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Drug-excipient compatibility studies
There is no alteration in the peaks of Ritonavir pure drug and 
optimized formulation, suggesting that there was no interaction takes 
place between drug and excipients and the spectrums are depicted in 
Figs. 15-17.
Figure 4: In vitro drug release profile of Ritonavir floating tablets 
F1–F7
Figure 5: In vitro drug release profile of Ritonavir floating tablets 
F8–F14
Figure 6: In vitro drug release profile of Ritonavir floating tablets 
F15–F21
Figure 7: Zero-order plots for the optimized formulation (F21)
Figure 8: First-order plots for the optimized formulation (F21)
Figure 10: Korsmeyer–Peppas plots for the optimized formulation 
(F21). In vitro drug release order kinetics for marketed product
Figure 11: Zero-order plots for the marketed product
Figure 12: First-order plot for the marketed product
Figure 13: Higuchi plot for the marketed formulation
Figure 9: Higuchi plots for the optimized formulation (F21)
Figure 14: Korsmeyer–Peppas plot for the marketed product
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DSC studies
Pure powdered Ritonavir showed melting endotherm at 122.10°C. 
DSC thermogram of floating tablet showed melting peak drug at 
119.36°C. There was no significant difference in melting point of drug 
and optimized formulation. It is compatible with excipients present 
in the tablet and there was no major interaction of the drug with the 
excipients; it is depicted in Figs. 18-21.
SEM studies of Ritonavir floating tablets
The SEM of optimized floating tablet shows a rough surface morphology 
and dented surface structure, but they showed good floating ability on 
medium, indicating that intact surface it is shown in Fig. 22. The shell 
of tablet also showed some porous structure and it may be due to the 
release of carbon dioxide.
Figure 15: Fourier-transform infrared spectroscopy of pure drug Ritonavir
Figure 16: Fourier-transform infrared spectroscopy of Ritonavir physical mixture
Figure 17: Fourier-transform infrared spectroscopy of Ritonavir optimized formulation
Figure 18: Differential scanning calorimetry thermogram of Ritonavir pure drug
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Stability studies
There were no changes observed in percentage drug content, in vitro 
drug release studies, and floating lag time during storage of the 
optimized formulation, and the results are tabulated in Table 7. Hence, 
the optimized formulation was found to be stable.
In vivo radiographic studies of Ritonavir optimized formulation (F21)
The behavior of the tablet in the dog stomach was observed in real time 
using a radiographic imaging technique. On radiographic images made 
0.5 h after the administration, the tablets were observed in the animal’s 
stomach. In the next picture taken at 1.5 h, significant changes were 
detected, and the tablet had altered its position and turned around. This 
provided evidence that the tablets did not adhere to the gastric mucus 
but, on the contrary, floated on the gastric fluid. In addition, the swelling 
of the tablet is visualized very well together with the white dry core 
and translucent swelling layer around it. As the swelling continued, 
the results have shown, in Fig. 23, that the mean gastric residence time 
for the developed floating tablets was 330 min±40. The comparison 
of gastric motility and stomach emptying between humans and dogs 
shows no big differences. Therefore, it might be speculated that 
experimentally proven increased GRT in beagle dogs can be compared 
to known literature data for humans.
CONCLUSION
In the present work, it can be concluded that the Ritonavir floating 
tablets can be an innovative and promising approach for the delivery 
and the treatment of HIV. The optimized formulation F21 contains 
HPMC K100M, Polyox WSR 303, and gas generating agent. In vitro 
release profile of Ritonavir and marketed product when compared 
the optimized formulation F21 showed drug release of 98.67±5.40%, 
whereas 91.46±5.02% of the drug was released from the marketed 
product within 24 h. The major mechanism of drug release follows 
zero-order kinetics and non-Fickian transport by coupled diffusion 
and erosion. This means that water diffusion and the polymer 
rearrangement have an essential role in the drug release. The release 
rate constant of optimized formulation F21 was low enough prolonging 
drug delivery. In vivo experiments supported the expectations in 
prolonging the gastric residence time in the fasted state in beagle dogs. 
The mean gastric residence time for the tested tablets was 330 min±40. 
This result is encouraging because a longer gastric residence time is an 
important condition for higher bioavailability of the drugs included in 
the prolonged or controlled release dosage form.
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